[Dopamine agonists situation in Parkinson disease].
The development of a variety of side effects associated with long term treatment of Parkinson s disease has prompted the introduction of new drugs and new treatment strategies. The use of dopamine agonists in combination with levodopa has proved to be useful in advanced patients with motor fluctuations. Recent studies indicate that the use of dopamine agonists in monotherapy from the early stages of the disease can be as effective as levodopa for clinical improvement with the added advantage of a significant less presentation of diskinesias. Ropinirol the first dopaminergic agonist demonstrating this effect in a 5 year controlled study, has well tolerance, both in combination or in monotherapy. Although low doses can be useful for individual patients, doses of approximately 15 16 mg/day proved to be safe and effective in long term studies.
Barbanoj
M
M
Laboratori del Son. Area Investigació Farmacològic; Hospital de la Santa Creu i Sant Pau, Barcelona, 08025, España.
Campos Arillo
V M
VM
Giménez-Roldán
S
S
Kulisevsky
J
J
Linazasoro Cristóbalampos
G
G
Luquin Piudo
M R
MR
Vela Desojo
L
L
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007211:Indoles; C046649:ropinirole
Situación de los agonistas dopaminérgicos en la enfermedad de Parkinson.